Claims extracted
16
sentences that state something as happening or true
Uncertain
12%
2 of 16 hedged
("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
94/100
City AM's corrections and
hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
A cancer drug venture backed by a group of celebrity investors and Middle Eastern wealth is planning to list on the London Stock Exchange.
asserted
venture → back → Exchange
Ellipses Pharma, a clinical-stage oncology venture founded by renowned British biotech entrepreneur Sir Chris Evans and, is preparing to reverse into a brand-new company, targeting a listing valuation of between £450m and £500m, according to reports in The Times.
uncertain
Pharma → found → Times
The company’s investors include Evans, founder of housebuilder Redrow, Steve Morgan, and Scottish entrepreneur Sir Tom Hunter’s investment vehicle West Coast Capital.
asserted
investors → include → Redrow
Celebrity investors have also thrown their weight behind Ellipses, including comedian Jimmy Carr and Andrew Lloyd Webber.
But the venture’s single largest investor is Abu Dhabi’s sovereign wealth fund, which holds a 45 per cent stake.
asserted
which → throw → stake
Waleed al- Mokarrab al-Muhairi, deputy chief executive of Mubadala Investment Company, the nation’s sovereign wealth fund, sat on the firm’s board until March 2025.
asserted
Muhairi → sit → March
It launched a clinical trial programme in the UAE in December 2024.
Seeing off the US
Evans, who has overseen the founding and listing of numerous biotech companies including Enzymatix and Celsis, had been weighing up a listing away from London.
asserted
who → launch → London
The entrepreneur was considering the Nasdaq for Ellipses’ home, while Hong Kong was also floated as a possible venue in 2025.
asserted
Kong → consider → 2025
But Ellipses is now targeting a listing in London as soon as February through a reverse takeover of Wolfram Resources, a cash shell which had been focused on investment in precious metals exploration across central Asia.
asserted
which → target → Asia
Private bank Berenberg is reported to have been appointed to help manage the deal, while Ellipses is also preparing to appoint non-executives to its board before a listing.
asserted
Ellipses → report → listing
Royal Bank of Canada and Pharma Ventures, an M&A advisory firm, are understood to have been lined up to advise on potential out-license deals with big pharma companies.
asserted
Bank → understand → companies
A formal announcement could be made as soon as this week.
uncertain
announcement → make → week
Boost for London
Reverse takeovers offer a fast-track route to raising money on public markets compared to an initial public offering and the Nasdaq has been hit with a flurry of such deals over the course of this year.
asserted
Nasdaq → offer → year
A successful listing would also provide London with a much needed boost, as it continues to feel the shocks of a wave of delistings coupled with a continued exodus of IPOs.
asserted
it → provide → IPOs
In particular, it would lift London’s biotech and pharmaceutical sector, which has seen companies eye opportunities in America.
asserted
companies → lift → America
FTSE heavyweight Astrazeneca has pivoted closer to the US over the last year, upgrading its listing on the New York stock Exchange.
asserted
Astrazeneca → pivot → Exchange
Ellipses employs around 40 people, mainly from big pharma companies, and has invested roughly £185m in its drug pipeline.
asserted
Ellipses → employ → pipeline